ARB 201
Alternative Names: ARB-201Latest Information Update: 28 Feb 2022
Price :
$50 *
At a glance
- Originator Arbele
- Class Antineoplastics; Bispecific antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Colorectal cancer
Most Recent Events
- 28 Feb 2022 No recent reports of development identified for preclinical development in Colorectal-cancer in Hong Kong (Parenteral)
- 21 Apr 2018 Pharmacodynamics data from preclinical trials in Colon cancer presented at the 109th Annual Meeting of the American Association of Cancer Research (AACR-2018)
- 01 Jan 2018 Preclinical trials in Colorectal cancer in Hong Kong (Parenteral)